JP7590351B2 - Ｐｒｍｔ５阻害剤を使用した癌の治療法 - Google Patents

Ｐｒｍｔ５阻害剤を使用した癌の治療法 Download PDF

Info

Publication number
JP7590351B2
JP7590351B2 JP2021571834A JP2021571834A JP7590351B2 JP 7590351 B2 JP7590351 B2 JP 7590351B2 JP 2021571834 A JP2021571834 A JP 2021571834A JP 2021571834 A JP2021571834 A JP 2021571834A JP 7590351 B2 JP7590351 B2 JP 7590351B2
Authority
JP
Japan
Prior art keywords
days
cancer
subsequent
period
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535406A5 (enExample
JP2022535406A (ja
Inventor
ジョイ ミラー クイン，ヒラリー
エリザベス パックマン，キャサリン
ハディッシュ－ベルハン，ナホー
エス．ジェイ． マネンス，ヘルト
ジョウ，ジュングオ
ティー． グレウェイ，アンソニー
ブレハマー，ダーク
グオ，ユエ
ウ，トンフェイ
シエ，ホン
ローリン，ジョシュ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022535406A publication Critical patent/JP2022535406A/ja
Publication of JP2022535406A5 publication Critical patent/JP2022535406A5/ja
Application granted granted Critical
Publication of JP7590351B2 publication Critical patent/JP7590351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021571834A 2019-06-06 2020-06-05 Ｐｒｍｔ５阻害剤を使用した癌の治療法 Active JP7590351B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858076P 2019-06-06 2019-06-06
US62/858,076 2019-06-06
EP19193850.5 2019-08-27
EP19193850 2019-08-27
PCT/EP2020/065639 WO2020245365A1 (en) 2019-06-06 2020-06-05 Methods of treating cancer using prmt5 inhibitors

Publications (3)

Publication Number Publication Date
JP2022535406A JP2022535406A (ja) 2022-08-08
JP2022535406A5 JP2022535406A5 (enExample) 2023-06-13
JP7590351B2 true JP7590351B2 (ja) 2024-11-26

Family

ID=70922068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571834A Active JP7590351B2 (ja) 2019-06-06 2020-06-05 Ｐｒｍｔ５阻害剤を使用した癌の治療法

Country Status (16)

Country Link
US (2) US11571437B2 (enExample)
EP (1) EP3980019A1 (enExample)
JP (1) JP7590351B2 (enExample)
KR (1) KR20220017989A (enExample)
CN (1) CN113966232A (enExample)
AU (1) AU2020286961A1 (enExample)
BR (1) BR112021024469A2 (enExample)
CA (1) CA3142825A1 (enExample)
IL (1) IL288665A (enExample)
JO (1) JOP20210320A1 (enExample)
MA (1) MA56095A (enExample)
MX (1) MX2021014944A (enExample)
PH (1) PH12021552841A1 (enExample)
SG (1) SG11202112439YA (enExample)
TW (1) TW202112375A (enExample)
WO (1) WO2020245365A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153161A1 (en) * 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115161341B (zh) * 2022-06-10 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528946A (ja) 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
JP2005527502A (ja) 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
JPWO2005005450A1 (ja) 2003-07-15 2006-08-24 三井化学株式会社 環状ビスジヌクレオチドの合成方法
EP1694642A4 (en) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc MUTAGENIC HETEROCYCLES
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
EP2043635A2 (en) 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
KR20120113228A (ko) 2009-12-18 2012-10-12 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 베타 세포 복제 촉진 화합물 및 그 사용 방법
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
JP5906253B2 (ja) 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
EP2694524B1 (en) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2942833A1 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
TN2019000087A1 (en) 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
TN2019000212A1 (en) 2017-02-27 2021-01-07 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528946A (ja) 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Participants With Advanced Cancers"，［online］，2019年05月，［2024年4月18日検索］，インターネット＜URL：https://classic.clinicaltrials.gov/ct2/history/NCT03573310?A=1&B=5&C=Side-by-Side#StudyPageTop＞
"History of Changes for Study: NCT02783300 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma"，［online］，2016年，［2024年4月18日検索］，インターネット＜URL：https://classic.clinicaltrials.gov/ct2/history/NCT02783300?A=1&B=20&C=Side-by-Side#StudyPageTop＞
"薬剤師のための抗がん薬治療スキルアップテキスト"，一般財団法人長崎県薬剤師会，2015年，pp.1-5
Bioorganic and Medicinal Chemistry Letters，2019年03月，Vol.29，pp.1264-1269
Cancer Research，2017年, Vol.77, No.13_Supplement，Abstract DDT02-04
Cancer Research，2018年, Vol.78, No.13_Supplement，Abstract 4859
Chemical and Pharmaceutical Bulletin，2019年04月，Vol.67, No.4，pp.382-388
FASEB Journal，2008年，Vol.22、No.3，p.659-661
International Journal of Biology and Biotechnology，2017年，Vol.14，No.3 pp.311-317
SCIENTIFIC REPORTS，2018年，Vol.8, Artilce No.9711，pp.1-15
医薬品情報学，2010年, Vol.11, No.4，pp.217-222
日本耳鼻咽喉科学会会報，2016年, Vol.119, No.5，pp.734-740

Also Published As

Publication number Publication date
KR20220017989A (ko) 2022-02-14
TW202112375A (zh) 2021-04-01
JP2022535406A (ja) 2022-08-08
CN113966232A (zh) 2022-01-21
WO2020245365A1 (en) 2020-12-10
US20200384006A1 (en) 2020-12-10
JOP20210320A1 (ar) 2023-01-30
CA3142825A1 (en) 2020-12-10
US20230241087A1 (en) 2023-08-03
SG11202112439YA (en) 2021-12-30
MX2021014944A (es) 2022-01-24
BR112021024469A2 (pt) 2022-01-18
AU2020286961A1 (en) 2022-02-03
MA56095A (fr) 2022-04-13
IL288665A (en) 2022-02-01
EP3980019A1 (en) 2022-04-13
US11571437B2 (en) 2023-02-07
PH12021552841A1 (en) 2022-10-03

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
US20230241087A1 (en) Methods Of Treating Cancer Using Prmt5 Inhibitors
US20250268899A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
EA034512B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
JP2017521396A (ja) 癌のための併用療法
AU2022355108A1 (en) Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
JP2023537595A (ja) 併用治療
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
RU2832833C1 (ru) Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком
HK40067831A (en) Methods of treating cancer using prmt5 inhibitors
US10857113B2 (en) Bezafibrate for the treatment of cancer
JP2019532937A (ja) Ｒｎａポリメラーゼｉ阻害に基づく、がんの併用治療戦略
JP2023519491A (ja) 癌関連疲労の治療に使用するためのｃｘｃｌ８阻害剤およびその医薬組成物
AU2023249645A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
HK40112852A (zh) 癌的治疗或预防用药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241114

R150 Certificate of patent or registration of utility model

Ref document number: 7590351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150